Cogent Biosciences (NASDAQ:COGT) Stock Falls 4.5% – Should You Sell?

Cogent Biosciences, Inc. (NASDAQ:COGT)’s stock price dropped 4.5% on Wednesday. The company traded as low as $30.98 and last traded at $30.2250. Approximately 208,606 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 2,157,045 shares. The stock had previously closed at $31.64.

More Cogent Biosciences News

Here’s some of the latest news about COGT:

• Positive Sentiment: HC Wainwright raised its FY2027 EPS estimate to a loss of $1.09 from $1.28 and lifted its Q3 2027 forecast from a loss to a profit of $0.19 per share. It also narrowed projected losses for Q2 and Q4 2027. The firm maintained its Buy rating and $56 price target, supporting a more optimistic longer-term outlook. HC Wainwright forecast article
• Neutral Sentiment: A separate report said COGT had moved above its 50-day moving average after its earnings release. That technical signal may indicate improving momentum, though it differs from the supplied snapshot, which places the shares below that average. Moving-average article
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $0.67 from $0.62 and its Q1 2027 estimate to a loss of $0.51 from $0.50, tempering the longer-term improvement. Cogent also recently reported a quarterly loss per share wider than analysts expected, adding near-term pressure.

Analyst Upgrades and Downgrades

COGT has been the topic of a number of recent analyst reports. HC Wainwright boosted their price target on shares of Cogent Biosciences from $55.00 to $56.00 and gave the company a “buy” rating in a research report on Monday. Wedbush reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a report on Wednesday, September 16th. Wall Street Zen cut shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. Guggenheim boosted their target price on Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Cogent Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.57.

Cogent Biosciences Trading Down 6.5%

The stock has a market capitalization of $5.13 billion, a P/E ratio of -13.16 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 10.99 and a quick ratio of 13.57. The business’s 50 day simple moving average is $31.74 and its 200-day simple moving average is $35.44.

Cogent Biosciences (NASDAQ:COGT) last issued its earnings results on Thursday, November 5th. The technology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). As a group, analysts forecast that Cogent Biosciences, Inc. will post -2.28 EPS for the current year.

Institutional Investors Weigh In On Cogent Biosciences

Several institutional investors have recently bought and sold shares of the company. J.Safra Asset Management Corp acquired a new position in Cogent Biosciences during the second quarter worth $27,000. Integrated Wealth Concepts LLC acquired a new position in shares of Cogent Biosciences during the 2nd quarter worth about $29,000. Parallel Advisors LLC acquired a new position in shares of Cogent Biosciences during the 1st quarter worth about $39,000. Quantbot Technologies LP bought a new position in shares of Cogent Biosciences in the 2nd quarter valued at about $53,000. Finally, EverSource Wealth Advisors LLC raised its holdings in Cogent Biosciences by 127.5% during the first quarter. EverSource Wealth Advisors LLC now owns 1,611 shares of the technology company’s stock worth $62,000 after acquiring an additional 903 shares in the last quarter.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.